Effectiveness of imipenem-relebactam for multidrug-resistant <i>Pseudomonas aeruginosa</i> in pneumonia and bloodstream infections in the United States (MIRAGE).

ABSTRACT: Imipenem-relebactam demonstrates in vitro activity against multidrug-resistant (MDR) Pseudomonas aeruginosa, but real-world effectiveness data are limited. MIRAGE was a multicenter, retrospective, observational study of imipenem-relebactam for MDR P. aeruginosa pneumonia and bacteremia. Patients were included if they received imipenem-relebactam for >48 h within 7 days of index P. aeruginosa culture. The primary outcome was clinical success at day 30, defined as survival, resolution of signs and symptoms of infection, completion of intended treatment course, and absence of recurrent infection. Secondary outcomes included 30- and 90-day mortality, infection recurrence, and development of non-susceptibility. Sixty-three patients were included. Median (IQR) age was

SUBMITTER: Wangchinda W 

PROVIDER: S-EPMC12691631 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature